Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

New York, New York


The purpose of the project is to investigate in eyes with dry AMD, the efficacy and safety as preventive therapy of the immunomodulatory substance named copaxone which had been proven as safe and effective agent for a neurodegenerative disease, in arresting the progression as well as the conversion of dry AMD to wet AMD. The hypothesis that the immunomodulatory agent copaxone proven for a neurodegenerative disease may work in the eye is revolutionary and may open a new avenue of preventive treatment for the disease which is the major cause of legal blindness in the industrial world


Inclusion Criteria: 1. Dry AMD in one or both eyes 2. Age 50 or above of either gender 3. Signed informed consent. Exclusion Criteria: 1. Known sensitivity to Mannitol or Copaxone. 2. Skin disease or active infection of skin. 3. Active fever or active treatment for infection. 4. History of other uncontrolled systemic active disease. 5. Premenopausal females not using reliable birth control. 6. Sensitivity to fluorescein or iodine. 7. Inability to comply with study procedures.



Primary Contact:

Principal Investigator
Richard B Rosen, MD
New York Eye and Ear Infirmary

Backup Contact:


Location Contact:

New York, New York
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: June 25, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.